• #729015
  • 672
  • Amgen Inc #55513071001

Prolia® Denosumab, Preservative Free 60 mg / mL Subcutaneous Injection Prefilled Syringe 1 mL

PROLIA, SYR 60MG/ML 1M

Features
  • Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
  • Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
  • More …
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #729015
Manufacturer #55513071001
BrandProlia®
ManufacturerAmgen Inc
Country of OriginGermany
Alternate Manufacturer Number1925965
ApplicationBone Resorption Inhibitor
Container TypePrefilled Syringe
Dosage FormInjection
Generic Drug Code28656
Generic Drug NameDenosumab, Preservative Free
NDC Number55513-0710-01
Product DatingMcKesson Acceptable Dating: we will ship >= 180 days
Storage RequirementsRequires Refrigeration
Strength60 mg / mL
TypeSubcutaneous
UNSPSC Code51182428
UserAdult
Volume1 mL
Features
  • Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
  • Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
  • All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
  • Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
  • Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
  • Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
  • Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
  • Protect Prolia from direct light and heat
More Information